A retrospective comparison of drugs against COVID-19.
Identifieur interne : 000651 ( Main/Corpus ); précédent : 000650; suivant : 000652A retrospective comparison of drugs against COVID-19.
Auteurs : Jiahong Tan ; Yuan Yuan ; Cheng Xu ; Chunyan Song ; Dan Liu ; Ding Ma ; Qinglei GaoSource :
- Virus research [ 1872-7492 ] ; 2021.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (pathology), Drug Combinations (MeSH), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunoglobulin G (blood), Immunoglobulin M (blood), Indoles (therapeutic use), Length of Stay (MeSH), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Oseltamivir (therapeutic use), Retrospective Studies (MeSH), Ritonavir (therapeutic use), SARS-CoV-2 (immunology), SARS-CoV-2 (isolation & purification), Young Adult (MeSH).
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G, Immunoglobulin M.
- chemical , therapeutic use : Adrenal Cortex Hormones, Hydroxychloroquine, Indoles, Lopinavir, Oseltamivir, Ritonavir.
- diagnosis : COVID-19.
- drug therapy : COVID-19.
- immunology : SARS-CoV-2.
- isolation & purification : SARS-CoV-2.
- pathology : COVID-19.
- Adult, Aged, Aged, 80 and over, Drug Combinations, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Young Adult.
Abstract
Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
DOI: 10.1016/j.virusres.2020.198262
PubMed: 33333102
PubMed Central: PMC7833729
Links to Exploration step
pubmed:33333102Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A retrospective comparison of drugs against COVID-19.</title><author><name sortKey="Tan, Jiahong" sort="Tan, Jiahong" uniqKey="Tan J" first="Jiahong" last="Tan">Jiahong Tan</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Yuan, Yuan" sort="Yuan, Yuan" uniqKey="Yuan Y" first="Yuan" last="Yuan">Yuan Yuan</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Cheng" sort="Xu, Cheng" uniqKey="Xu C" first="Cheng" last="Xu">Cheng Xu</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Song, Chunyan" sort="Song, Chunyan" uniqKey="Song C" first="Chunyan" last="Song">Chunyan Song</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Dan" sort="Liu, Dan" uniqKey="Liu D" first="Dan" last="Liu">Dan Liu</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Ma, Ding" sort="Ma, Ding" uniqKey="Ma D" first="Ding" last="Ma">Ding Ma</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Gao, Qinglei" sort="Gao, Qinglei" uniqKey="Gao Q" first="Qinglei" last="Gao">Qinglei Gao</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China. Electronic address: qingleigao@hotmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33333102</idno><idno type="pmid">33333102</idno><idno type="doi">10.1016/j.virusres.2020.198262</idno><idno type="pmc">PMC7833729</idno><idno type="wicri:Area/Main/Corpus">000651</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000651</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A retrospective comparison of drugs against COVID-19.</title><author><name sortKey="Tan, Jiahong" sort="Tan, Jiahong" uniqKey="Tan J" first="Jiahong" last="Tan">Jiahong Tan</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Yuan, Yuan" sort="Yuan, Yuan" uniqKey="Yuan Y" first="Yuan" last="Yuan">Yuan Yuan</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Cheng" sort="Xu, Cheng" uniqKey="Xu C" first="Cheng" last="Xu">Cheng Xu</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Song, Chunyan" sort="Song, Chunyan" uniqKey="Song C" first="Chunyan" last="Song">Chunyan Song</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Dan" sort="Liu, Dan" uniqKey="Liu D" first="Dan" last="Liu">Dan Liu</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Ma, Ding" sort="Ma, Ding" uniqKey="Ma D" first="Ding" last="Ma">Ding Ma</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</nlm:affiliation></affiliation></author><author><name sortKey="Gao, Qinglei" sort="Gao, Qinglei" uniqKey="Gao Q" first="Qinglei" last="Gao">Qinglei Gao</name><affiliation><nlm:affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China. Electronic address: qingleigao@hotmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Virus research</title><idno type="eISSN">1872-7492</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Viral (blood)</term><term>COVID-19 (diagnosis)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (pathology)</term><term>Drug Combinations (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunoglobulin G (blood)</term><term>Immunoglobulin M (blood)</term><term>Indoles (therapeutic use)</term><term>Length of Stay (MeSH)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Oseltamivir (therapeutic use)</term><term>Retrospective Studies (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (immunology)</term><term>SARS-CoV-2 (isolation & purification)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Hydroxychloroquine</term><term>Indoles</term><term>Lopinavir</term><term>Oseltamivir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33333102</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>294</Volume><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>A retrospective comparison of drugs against COVID-19.</ArticleTitle><Pagination><MedlinePgn>198262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(20)31169-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2020.198262</ELocationID><Abstract><AbstractText>Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Jiahong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qinglei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China. Electronic address: qingleigao@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>93M09WW4RU</RegistryNumber><NameOfSubstance UI="C086979">umifenovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Arbidol</Keyword><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Corticosteroids</Keyword><Keyword MajorTopicYN="Y">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">Lopinavir/ritonavir</Keyword><Keyword MajorTopicYN="Y">Oseltamivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33333102</ArticleId><ArticleId IdType="pii">S0168-1702(20)31169-2</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2020.198262</ArticleId><ArticleId IdType="pmc">PMC7833729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 2020 Apr 7;323(13):1239-1242</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2020 Sep 09;11:571156</Citation><ArticleIdList><ArticleId IdType="pubmed">33013412</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudi Pharm J. 2020 Dec;28(12):1877-1882</Citation><ArticleIdList><ArticleId IdType="pubmed">33020690</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2020 Sep 17;11:585888</Citation><ArticleIdList><ArticleId IdType="pubmed">33041830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2020 Nov;40(11):1072-1081</Citation><ArticleIdList><ArticleId IdType="pubmed">33044019</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Chem. 2017;24(20):2241-2249</Citation><ArticleIdList><ArticleId IdType="pubmed">28302011</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 22;368(6493):829-830</Citation><ArticleIdList><ArticleId IdType="pubmed">32385101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2016 Jan 06;90(6):3086-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26739045</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Transl Med. 2020 Jul;10(3):e119</Citation><ArticleIdList><ArticleId IdType="pubmed">32696591</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Transl Immunology. 2020 May 06;9(5):e01136</Citation><ArticleIdList><ArticleId IdType="pubmed">32382418</ArticleId></ArticleIdList></Reference><Reference><Citation>AMB Express. 2020 May 15;10(1):92</Citation><ArticleIdList><ArticleId IdType="pubmed">32415548</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation><ArticleIdList><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2020 Sep 30;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33028485</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 2001;61(2):263-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11270942</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2020 Jun;27(6):493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">32359203</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):769-777</Citation><ArticleIdList><ArticleId IdType="pubmed">32176772</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharmacol Rep. 2020 May 11;:1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">32395418</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr;92(4):401-402</Citation><ArticleIdList><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation><ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Ther. 2020 May 6;14(2):67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">32336723</ArticleId></ArticleIdList></Reference><Reference><Citation>New Microbes New Infect. 2020 Nov;38:100776</Citation><ArticleIdList><ArticleId IdType="pubmed">33042552</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Dec 2;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2020 Apr;25(15):</Citation><ArticleIdList><ArticleId IdType="pubmed">32317050</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):105-113.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Jun 13;395(10240):1845-1854</Citation><ArticleIdList><ArticleId IdType="pubmed">32450106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2020 Nov;30(6):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">32779326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation><ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e209035</Citation><ArticleIdList><ArticleId IdType="pubmed">32330276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2020 Jul;157:104859</Citation><ArticleIdList><ArticleId IdType="pubmed">32360480</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2002 Jul-Aug;36(7-8):1193-203</Citation><ArticleIdList><ArticleId IdType="pubmed">12086554</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Mol Sci. 2020 Apr 10;21(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">32290293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2020 Oct;143:110110</Citation><ArticleIdList><ArticleId IdType="pubmed">33017904</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2020 Apr 14;52(4):583-589</Citation><ArticleIdList><ArticleId IdType="pubmed">32259480</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Chem Lett. 2020 Aug 14;:1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">32837486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33333102
|texte= A retrospective comparison of drugs against COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33333102" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |